New hope for tough prostate cancer: experimental therapy targets resistant tumors
Disease control
Recruiting now
This study is testing a new immunotherapy called SV-102 for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. Researchers will give the treatment directly into tumors to find the safest and most effective dose while checking …
Phase: PHASE2 • Sponsor: Syncromune, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC